CDH1 and breast cancer: A recent meta-analysis of breast cancer patients carried out by Li et al. [102] revealed that reduction of E-cadherin on tumor cells was significantly associated with poorer overall survival and disease-free survival, and correlated with clinicopathological features such as tumor size, lymph node status, TNM stage and histological grade [18,103].